Lennox-Gastaut syndrome
ICD-10 G40.4 · ICD-11 8A62.1

Treatment of Lennox-Gastaut Syndrome That Has Evolved from Another Epilepsy Syndrome

Clinical scenario

Lennox-Gastaut syndrome (LGS) does not always arise de novo. Many patients progress to LGS over time from another epilepsy syndrome — such as infantile epileptic spasms syndrome (IESS) — and will have been receiving antiseizure medication (ASM) therapy prior to the LGS diagnosis.

This protocol addresses the specific situation where LGS has evolved from a prior epilepsy syndrome and the patient is not already being treated with sodium valproate. In this scenario, the prior treatment history directly shapes how the transition to appropriate LGS management is structured.

Why this scenario requires a specific approach

Patients with LGS that has evolved from another type of epilepsy who are not already being treated with valproate require transition to valproate and subsequent management following the same algorithm applied in newly diagnosed LGS. The existing ASM regimen — whether a single agent or a combination — determines how that transition is carried out.

Treatment approach — partial overview

The protocol centres on initiating sodium valproate therapy alongside a structured transition away from the patient's existing non-valproate antiseizure regimen. Whether the patient is on a single first-line ASM or on more than one ASM determines exactly how the transition proceeds.

The complete sequencing, tapering strategy, and subsequent management steps are detailed in the full structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1002/epi4.13075

Patients with LGS that has evolved from another type of epilepsy who are not already being treated with valproate should be transitioned to valproate and then managed using the same algorithm as for newly diagnosed LGS.

Many patients will either have been treated with ASM therapy to initially control seizures before LGS diagnosis or will have developed LGS having progressed over time from another epilepsy syndrome, such as IESS.

If the patient is already being treated with another first-line ASM (typically LEV), then VPA therapy should be initiated and the other therapy tapered off and discontinued.

If the patient is being treated with more than one ASM and neither is VPA, then VPA therapy should be initiated and one of the previous ASMs tapered off and discontinued.

View source ↗